Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation will be webcast and available for 30 days. The company continues to focus on organic growth of its commercial portfolio, plasma collection operations, and pursuing M&A opportunities.

Kamada Ltd. announced FDA approval of its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Beit Kama, Israel. The facility will enhance quality control and testing capabilities for the company's rabies immunoglobulin products KEDRAB and KAMRAB, which generated over $70 million in 2025 sales. The laboratory represents a significant expansion of Kamada's advanced testing capabilities and demonstrates the company's commitment to innovation and operational efficiency.

Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced it will release its first quarter 2026 financial results on May 13, 2026, followed by a management conference call. The company operates three FDA-approved plasma collection centers in Texas and focuses on growth through its commercial portfolio of specialty plasma products, third-party pharmaceutical distribution, plasma collection operations, and strategic M&A opportunities.

Kamada Ltd. announced FDA approval of its San Antonio, Texas plasma collection center following an on-site inspection in February 2026. The 11,100 square foot facility has a planned capacity of approximately 50,000 liters per year and is expected to generate $8-10 million in annual revenues from normal source plasma sales at full capacity. The center is anticipated to be one of the largest specialty plasma collection centers in the U.S., complementing Kamada's existing operations in Houston and Beaumont, Texas.

Kamada reported strong financial performance in Q3 2025, with revenues of $47.0 million (up 13% year-over-year) and adjusted EBITDA of $11.7 million (up 34%). The company reiterated its full-year revenue guidance of $178-$182 million and continues to focus on business development and plasma collection operations.

Kamada Ltd. will release its Q3 and nine-month financial results on November 10, 2025, and will host an investment community conference call to discuss the results.

Kamada Ltd., a global biopharmaceutical company, announced that it will release its financial results for the fourth quarter and fiscal year ended December 31, 2024, on March 5, 2025. The company will host an investor conference call to discuss the results.

Alvotech, a biopharmaceutical company, will hold an investor presentation on March 27, 2025, following the release of its Q4 2024 and full-year 2024 financial results. The presentation will be held at the company's headquarters and will be webcast.

REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024.

REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer.

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and first nine months ended September 30, 2023, prior to the open of the U.S. financial markets on Monday, November 13, 2023.

REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that while circumstances in Israel are evolving, the Company continues to conduct its business operations in Israel with no effect on business continuity, and its global supply of products is not expected to be interrupted. Kamada will provide further updates if and when material events so warrant.